•  home page
  •  location & contact
  • Español
entrechem entrechem
  • about us
    • founders
    • key personnel
    • funding
    • strategy
  • pipeline
    • pipeline chart
    • EC-8042
    • EC-70124
  • technology
    • natural products
    • synthetic biology
    • biocatalysis
      • DA · enantiomerically pure chiral diamines
      • AA · enantiomerically pure chiral amino alcohols
      • IA · enantiomerically pure chiral amino indanes
  • collaborations
    • scientific collaborators
    • collaborative projects
  • publications
    • EC-8042
    • EC-70124
    • biocatalysis
    • synthetic biology
  • news
entrechem entrechem
  • about us
    • founders
    • key personnel
    • funding
    • strategy
  • pipeline
    • pipeline chart
    • EC-8042
    • EC-70124
  • technology
    • natural products
    • synthetic biology
    • biocatalysis
      • DA · enantiomerically pure chiral diamines
      • AA · enantiomerically pure chiral amino alcohols
      • IA · enantiomerically pure chiral amino indanes
  • collaborations
    • scientific collaborators
    • collaborative projects
  • publications
    • EC-8042
    • EC-70124
    • biocatalysis
    • synthetic biology
  • news
Sep 16

EntreChem SL closes financing round to develop new molecules for oncology

EntreChem closed a financing round thanks to a mix of private and public funding, in a deal that significantly strengthens the capacities of research and development of the biotech company. New shareholders include family offices and owners of industrial, long-running businesses, like NalonChem SA, as well as Alvargonzález SA and... read more →
  • 16 September, 2010
  • Financing
Feb 04

AENOR grants EntreChem UNE-166002 certification, an standard for the implementation of a quality R&D management system

AENOR (Spanish Association for Standarization and Certification) has granted EntreChem with the UNE-166002 certification, an standard for the implementation of a quality R+D+I system that contributes to optimising an organisation's technological research, development and innovation processes, enabling emerging technologies or new technologies applied to the sector to be recognised and... read more →
  • 4 February, 2010
  • Other
Jan 25

EntreChem awarded NEOTEC-2 financing from CDTI

The Centre for the Development of Industrial Technology (CDTI) has awarded EntreChem with a NEOTEC-2 grant, consisting on a special loan (a reimbursable loan) of 658.050 EUR for development of new antitumoral molecules. This loan carries a 0% interest rate and its reimbursable anytime contingent to positive cash-flow of the... read more →
  • 25 January, 2009
  • Financing
Jul 13

EntreChem study selected for poster presentation at the 20th EORTC-NCI-AACR symposium on “Molecular Targets and Cancer Therapeutics” held in Geneva from 21-24 October 2008

EntreChem data on the first family of antitumoral molecules being developed by the company have been selected for a poster presentation at the 20th ENA symposium held in Geneva from 21-24 October 2008. The principal investigator is Dr. Carlo Catapano, from the Istituto Oncologico della Svizzera Italiana (IOSI) in Bellinzona... read more →
  • 13 July, 2008
  • Other
Jul 31

EntreChem and Biomar SA enter a collaborative agreement
to develop new compounds

EntreChem has entered a development agreement with Instituto Biomar SA (León, Spain) to exploit EntreChem proprietary technology regarding the use of combinatorial biosynthesis and biotransformations for the generation of molecular diversity on certain Instituto Biomar proprietary compounds. About Instituto Biomar SA: Instituto Biomar... read more →
  • 31 July, 2007
  • Agreements
Oct 25

EntreChem and Laboratoires Servier sign R&D collaborative agreement

EntreChem has entered a collaborative agreement with Laboratoires Servier (Paris, France) to exploit EntreChem proprietary technology regarding the use of combinatorial biosynthesis and biotransformations for the generation of molecular diversity on Laboratoires Servier proprietary compounds. About Servier: Les Laboratoires Servier is the leading... read more →
  • 25 October, 2006
  • Agreements
Sep 19

EntreChem’s cofounder interviewed for Nature Biotechnology Special Report “Biotech in Spain”

Dr. Francisco Morís, co-founder and CEO of EntreChem, is interviewed in the September issue of Nature Biotechnology. The issue runs a Special Report about Biotech companies in Spain. Read the full article and Dr. Morís comments Nature Biotechnology, September 2006 issue nature_spain_report.pdf (3.1 MB)
  • 19 September, 2006
  • Other
Sep 04

C&EN News cover story mentions EntreChem glycosylation
engineering technology

Professor of biology José Salas and coworkers at the University of Oviedo, Spain, use a different tack. They insert into microorganisms plasmids that endow them with the ability to synthesize novel sugars, which are then transferred to natural products by glycosyltransferases. "Because glycosyltransferases are relatively flexible in their ability to... read more →
  • 4 September, 2006
  • Publications
Jun 22

EntreChem enters financing agreement with CDTI

EntreChem has signed an agreement with The Centre for the Development of Industrial Technology (CDTI) consisting on a reimbursable loan of 400,000 EUR within the NEOTEC program for promotion of newly created companies focused on technology development. The entities that may receive financing in the form of loans granted by... read more →
  • 22 June, 2006
  • Financing
Apr 01

EntreChem secures financing from SRP

EntreChem has signed an agreement with the “Sociedad Regional de Promoción” of the Principality of Asturias for a special loan (a “participative loan”) to finance start-up activities of EntreChem. This “participative loan” has an interest rate determined by company profits and its callability is subordinated to the other common creditors.... read more →
  • 1 April, 2006
  • Financing
  • 1
  • 2
  • 3
  • 4

« Previous Page — Next Page »

latest news

  • AI-Therapeutics acquires the preclinical drugs EC-8042 and EC-70124 from EntreChem SL
  • EC-8042 targets SWI/SNF complex vulnerabilities and induces epigenetic reprogramming and permanent cures in rhabdoid tumor
  • EntreChem participates in the ERA-Co-Biotech project «MISSION»

categories

  • Agreements
  • Financing
  • Projects
  • Publications
  • Research
  • Other

archive

EntreChem, S.L.

Vivero Ciencias de la Salud,
c/ Colegio Santo Domingo de Guzmán s/n,
33011 Oviedo, Spain

info@entrechem.com

pipeline  /  chart
· EC-8042
· EC-70124

scientific collaborators
collaborative projects

  • about us
  • technology
  • publications
  • news
Copyright © 2023 EntreChem, S.L. All rights reserved.
  • privacy policy
  • usage policy
  • cookies policy

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

Privacy Overview
entrechem

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!

Cookie Policy

You can consult our cookies policy for more information.